SHIFT NEWSROOM
Find the story, understand its context and follow the sources behind the headline.
Read the latest storiesEvidence ledReal sources, not speculation.
Context firstPlain English. No hype.
Built for menHealth news that matters to you.
YOUR READING LIST
182 published stories.
Find the stories that matter to you.
Showing 182 of 182 stories
Clear filtersDates show first publication in SHIFT. Original source dates are recorded in each article.
Submitted source
An offshore-industry weight restriction takes effect from1November2026. Under Offshore Energies UK's policy, workers over124kg in their travel clothing and shoes cannot travel offshore to the installations covered by the policy.
Submitted source
A report published on29October found substantial differences in recorded NHS GLP-1 prescribing between Scottish health boards. It raises questions about how accepted medicines reach patients, but does not tell an individual whether they can obtain treatment today.
MHRA
MHRA has updated Yellow Card reporting ahead of 2–8 November’s campaign. You can report a suspected medicine side effect without proving the cause.
House of Commons Library
MPs debated prostate screening on 26 October. The minister said PSA-testing policy had not changed; England’s targeted programme is planned for 2027.
Eli Lilly and Company newsroom
Lilly reported Phase 3 results on 28 October 2026.
UK Parliament
A parliamentary report calls for clearer access and continuing support. These recommendations do not change NHS eligibility.
Research update
Viking says SUNRISE tablet trials are underway. Records checked on 29 October still list estimated November starts and no posted results.
MHRA
Catch-up: UK authorisation announced on 13 October 2026.
Europe PMC
Catch-up: original trial paper published 30 September 2026; this summary uses its indexed abstract.
European Medicines Agency
Catch-up: opinion adopted 15 October and published by EMA on 16 October 2026.
Research update
Catch-up: Phase 3 dosing announced 23 September; separate EASD research release dated 1 October 2026.
MHRA
Catch-up: safety communication published 15 October 2026.
MHRA
Catch-up: raid on 14 October; regulator report published 15 October 2026.
MHRA / The Times
Why impressive packaging cannot replace medicine authorisation, prescription checks and a verified pharmacy.
Association of Anaesthetists
New UK findings underline why your surgical team needs to know about your weight-management medicine, including private prescriptions.
MHRA
The MHRA’s 2024 review reinforced monitoring when the medicine is used to suppress milk production after childbirth.
MHRA
The MHRA’s 2025 reminder emphasises anti-inflammatory treatment alongside short-acting reliever prescribing.
MHRA
The MHRA identified a small Guillain–Barré syndrome risk in older adults while retaining a favourable benefit–risk assessment.
MHRA
A historical update explains the service survey and remote-care clarifications, with the subsequent January 2026 changes linked.
MHRA
The MHRA called for warnings after a safety review; the medicine’s benefit-risk balance for approved uses was unchanged.
MHRA
January 2026 guidance changed prescribing for under-18s while retaining pregnancy prevention and side-effect monitoring.
MHRA
Updated 24 October 2026: the UK authorisation withdrawal announced on 20 October supersedes the older restrictions covered by this archive.
MHRA
Updated 24 October 2026: the UK authorisation withdrawal announced on 20 October supersedes the older restrictions covered by this archive.
MHRA
The MHRA has added a restriction for confirmed or suspected phaeochromocytoma after reports of severe hypertension.
ASA / CAP
The 2 September 2026 ruling upheld both complaints.
ASA / CAP
The ASA upheld two issues on 29 July 2026.
NHS England
UK archive · Original report: 8 November 2025. England’s remission programme expanded in 2024/25. Its supervised treatment and follow-up matter as much as the headline enrolment figure.
NHS England
UK archive · Original report: 30 December 2025. Nearly a million people had started England’s prevention programme by December 2025. The offer is support for elevated risk, not diabetes treatment.
NHS England
UK archive · Original report: 18 February 2026. A February 2026 NHS campaign highlighted anxiety conditions that people may overlook, including OCD, panic and post-traumatic stress.
NHS England
UK archive · Original report: 14 February 2026. The NHS-backed study links volunteers’ samples, questionnaires and records. Its initial recruitment announcement covered England and Wales.
NHS England
UK archive · Original report: 6 November 2025. The November 2025 final report called for better support across health, education and work. Recommendations need to be distinguished from local delivery.
NHS England
UK archive · Original report: 11 September 2025. New staff training announced in September 2025 focused on understanding a person’s needs and safety, rather than relying on a risk label.
SAMH
UK archive · Original report: 17 June 2026. SAMH opened its second Nook in Aberdeen in June 2026, adding another free, non-clinical place to talk without a referral.
NHS England
UK archive · Original report: 21 February 2026. NHS interest in blood-pressure advice rose during 2025. England’s pharmacy checks and NHS Health Check offer practical routes to assessment.
NHS England
UK archive · Original report: 6 May 2025. An NHS update described wider use of CT-based heart analysis in May 2025. The research concerns diagnosis and testing, not a guaranteed survival benefit.
NHS England
UK archive · Original report: 1 August 2026. Men with current or past prostate cancer are being invited to share their experiences and link records for research. This is not a screening invitation.
NHS England
UK archive · Original report: 11 July 2026. England’s July 2026 update found lower participation among younger invitees. A home screening kit is for people without symptoms.
NHS England
UK archive · Original report: 10 June 2026. NHS England announced wider access to five-session prostate radiotherapy in June 2026. Suitability remains a specialist decision.
Mental Health UK
UK archive · Original report: 20 May 2026. A May 2026 charity report examined confidence, job-seeking and transitions into work. Its findings challenge simple assumptions about motivation.
Mental Health UK
UK archive · Original report: 18 November 2025. Mental Health UK’s 2025 polling found both perceived benefits and reported harms. Self-reported experience is not proof of clinical effectiveness.
Scottish Government
UK archive · Original report: 21 October 2025. The 2024 survey, published in October 2025, links population health reporting with important cautions about screening measures and corrected tables.
Welsh Government
UK archive · Original report: 25 February 2026. A February 2026 announcement set out a specialist gambling service and helpline for Wales, including support for affected family members.
Public Health Scotland
UK archive · Original report: 28 July 2026. Public Health Scotland began reporting pilot activity in July 2026. Different opening dates and local arrangements make simple league tables misleading.
Public Health Scotland
UK archive · Original report: 7 July 2026. The 2025/26 MAT report examines treatment delivery across Scotland. Revised assessment criteria mean its scores cannot simply be compared with last year.
NIHR
UK archive · Original report: 7 September 2026. An NHS trial reported better quality of life with supervised support. The related activity programme has a specific referral route, not open national enrolment.
University of Bristol
UK archive · Original report: 23 September 2025. A study of UK GP records found greater weight gain after severe mental illness diagnoses, without a corresponding increase in structured referrals.
University of Oxford
UK archive · Original report: 30 June 2025. Oxford’s trial tested an add-on treatment for difficult-to-treat depression. Symptom improvements must be considered alongside tolerability.
Department of Health Northern Ireland
UK archive · Original report: 26 November 2025. The 2024/25 survey offers local context for weight and mental health. Its methods matter when interpreting changes and comparing nations.
NIHR
UK archive · Original report: May 2026. The UK trial tested supportive texts with and without incentives. Longer follow-up makes the outcome more nuanced than the original cash-reward headline.
NHS England
UK archive · Original report: 25 May 2026. England’s May 2026 update reported more than 10,000 cancers detected since rollout began. The screening offer targets an assessed higher-risk group.
NIHR
UK archive · Original report: July 2025. The July 2025 research report examined supported discontinuation for selected, well patients. It does not suggest that everyone should stop treatment.
NIHR
UK archive · Original report: 4 June 2026. Additional funding announced in June 2026 aims to widen Black men’s participation. Expansion is staged, with invitations rather than self-referral.
Public Health Scotland
UK archive · Original report: 25 August 2026. An August 2026 briefing asks whether positive initial destinations turn into sustained opportunities for young people whose health limits participation.
NHS England
An October evaluation update adds learning about pharmacy cholesterol checks and follow-up. The wider pilot remains limited to participating pharmacies.
UCL
UK archive · Original report: 4 August 2025. A small UK feeding trial compared two diets that both followed healthy-eating guidance. The result deserves attention, with limits.
UCL
UK archive · Original report: 8 January 2026. A Great Britain survey published in January 2026 offers a snapshot of medicine use, including a marked difference between men and women.
NICE
UK archive · Original report: 5 August 2025. NICE’s August 2025 quality standard put support after treatment in focus. NHS England’s 2026 guidance keeps that issue relevant.
NHS England
UK archive · Original report: 2 April 2026. April 2026 commissioning guidance explains phased access to tirzepatide, and why national eligibility is not the same as an immediate prescription.
NHS England
UK archive · Original report: 9 June 2025. Positive feedback from men who completed talking therapies is encouraging. It is a satisfaction finding, not a 92% cure rate.
NHS England
UK archive · Original report: 17 July 2025. The first of six neighbourhood mental-health pilots opened in July 2025, bringing clinical and practical support into one local service.
Department of Health and Social Care
UK archive · Original report: 5 August 2026. A £343 million announcement covers 100 community centres and 59 mental-health emergency departments. Many are planned facilities, rather than services open today.
Department of Health and Social Care
UK archive · Original report: 18 November 2025. The November 2025 strategy brought men’s physical and mental health together. Its commitments still need to be judged by delivery.
Welsh Government
UK archive · Original report: 30 April 2025. Wales published a new mental-health and wellbeing strategy in April 2025, alongside an initial delivery plan running to 2028.
Scottish Government
UK archive · Original report: 11 June 2025. A June 2025 update reviewed Scotland’s mental-health delivery and workforce plans, including progress and the pressures on implementation.
Department of Health Northern Ireland
UK archive · Original report: 29 June 2026. The June 2026 update set out a staged obesity-management service and a separate lifestyle programme. Their entry routes should not be confused.
NHS England
UK archive · Original report: 27 November 2025. The 2023/24 Adult Psychiatric Morbidity Survey, published in stages during 2025, helps describe need. Its figures are not a live count for 2026.
MHRA
UK archive · Original report: 10 August 2026. The MHRA’s August 2026 decision covers weight management and type 2 diabetes. It does not by itself create NHS access or confirm private stock.
Scottish Government
UK archive · Original report: 17 June 2025. Two ten-year frameworks published in June 2025 placed prevention, healthier food environments and care closer to home on Scotland’s agenda.
Mental Health UK
UK archive · Original report: 16 January 2026. Mental Health UK’s 2026 survey highlights the gap between mental-health awareness and practical support at work.
NHS England
What the planned expansion means for local pharmacy care, including who can provide it and what to check before travelling.
Europe PMC
A narrative review preprint examines family support, behavioural care and medicine-related research in childhood obesity. This version has not been peer reviewed.
Europe PMC
A Danish register study compared people starting GLP-1 medicines with those starting SGLT2 inhibitors for type 2 diabetes, with additional analyses in obesity.
Europe PMC
A preprint examines obesity and GLP-1 prescribing in a large integrated health system. It has not been peer reviewed.
Europe PMC
This review considers how diet and GLP-1 biology may interact in metabolic health and ageing. It brings together existing evidence rather than testing a new treatment in patients. It does not establish that all uses are safe, or support an individual treatment recommendation.
Europe PMC
This matched retrospective analysis found an association between GLP-1 receptor agonist use and lower periprosthetic joint-infection risk after knee replacement. It does not prove that the medicines prevent infection. Findings for other surgical outcomes differed.
Europe PMC
A retrospective study in Shoulder & Elbow examined adults with type 2 diabetes undergoing rotator cuff repair.
Europe PMC
A review in Clinics in Dermatology discusses access, affordability, informed consent, product quality and prescribing responsibilities as GLP-1 medicines are explored in skin care.
Europe PMC
This review proposes that some measured lean-mass reduction may reflect adaptation to a lighter body.
Europe PMC
A viewpoint in the Journal of Medical Internet Research proposes that digital behavioural support could help during and after GLP-1 treatment.
Europe PMC
A PLOS ONE protocol describes a retrospective study across three Swiss institutions examining GLP-1 exposure and progression of intraductal papillary mucinous neoplasms, a type of pancreatic cystic tumour.
Europe PMC
This retrospective Chinese study compared outcomes among people with type 2 diabetes using GLP-1 receptor agonists or other medicines. Its findings are associations and may be affected by differences between groups. They do not establish causation or a UK treatment recommendation.
PubMed / NLM
A new clinical practice statement from the Obesity Medicine Association highlights the link between obesity and cardiovascular disease
Europe PMC
A Biomedical Journal review explains molecular design. It is not a new clinical trial.
Europe PMC
The cited paper reports results from randomised, placebo-controlled phase 1a and 1b studies of UBT251, rather than announcing that those studies are only beginning.
Europe PMC
This Bayesian meta-analysis is a preprint and has not been peer reviewed in the version cited.
Europe PMC
This international expert-panel review discusses resmetirom and semaglutide for MASH and fibrosis in the regulatory context covered by its authors. It is not a new comparative trial. Current UK product authorisation, eligibility and NHS access need separate official verification.
ClinicalTrials.gov
Registry status checked on 3 October 2026: not yet recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: not yet recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: active not recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: not yet recruiting.
Europe PMC
This review describes current and emerging obesity medicines. Regulatory discussion reflects the jurisdictions covered by the paper and does not independently establish current UK authorisation or NHS availability.
Europe PMC
A study in Gut and Liver examined reflux reporting signals in adverse-event databases from the US, Japan and Canada.
Europe PMC
Researchers explore potential link between GLP-1 receptor agonist exposure and non-arteritic anterior ischaemic optic neuropathy in an illustrative case.
Europe PMC
The cited item is a letter in Diabetes, Obesity and Metabolism about patterns of GLP-1-based therapy use before and after pregnancy.
Europe PMC
This narrative review discusses potential dermatological uses and remaining evidence gaps. Proposed applications are not proof of an established treatment benefit or a new licensed indication.
Europe PMC
This preliminary evidence synthesis is a preprint, not a peer-reviewed clinical guideline.
PubMed / NLM
This review brings together evidence on GLP-1 receptor agonists in osteoarthritis and inflammatory arthritis. The evidence varies by condition and study design. It is not a new trial demonstrating an established benefit for all forms of arthritis.
Europe PMC
A review in Clinics in Dermatology discusses clinical studies, case reports and spontaneous reports of skin and injection-site reactions.
Europe PMC
Researchers are investigating the potential of Glucagon-Like Peptide-1 Receptor Agonists in treating Obstructive Sleep Apnea, but more evidence is needed.
PubMed / NLM
An observational study in Arthroplasty Today examined preoperative GLP-1 use among people having hip or knee replacement.
Europe PMC
This narrative review traces the development of obesity medicines and discusses named treatments. It summarises existing evidence rather than reporting a new clinical trial. Medicine-specific results, limitations and current UK access should be checked separately.
Europe PMC
Recent advances in the treatment of obesity and type 2 diabetes have been reported in a new research update.
PubMed / NLM
This review examines incretin-based treatments during adolescence. It summarises existing research rather than reporting a new trial. Adolescent eligibility, licensed indications and specialist care differ from an adult weight-management service.
PubMed / NLM
An Appetite review explores two approaches to obesity research without declaring a winner.
PubMed / NLM
A systematic review explores the link between obesity and heart failure with preserved ejection fraction (HFpEF), providing a therapeutic framework for treatment.
PubMed / NLM
A systematic review examines intake, body composition and reported malnutrition—not just weight loss.
Europe PMC
This review discusses existing and forthcoming pharmacotherapies for adolescent obesity, including medicine-specific evidence and safety considerations. It is not a new efficacy trial. Adolescent licensing and specialist-care requirements need current UK sources.
Europe PMC
This review discusses evidence for GLP-1-based treatments in MASH-related fibrosis. Results come from the studies it reviews; it is not a new treatment trial. Different agents have different evidence and regulatory status. UK authorisation and NHS access need separate current official checks.
Europe PMC
Researchers are investigating the use of GLP-1 receptor agonists after bariatric surgery, with a new trial publishing its rationale, design, and baseline characteristics.
PubMed / NLM
A study published on PubMed explores the impact of glucagon-like peptide-1 receptor agonists on chemosensory function and ingestive behavior, but more evidence is needed to fully understand their effects.
Europe PMC
Researchers have published an updated systematic review on the efficacy and safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for weight loss in adults without diabetes.
Europe PMC
A study in Diabetes, Obesity and Metabolism combined spontaneous adverse-event reports with regulatory and medicine-use information.
Europe PMC
A JCEM Case Reports article describes one man who lost more weight after switching from tirzepatide to semaglutide.
Europe PMC
An observational study followed seventy people with obesity and type 1 diabetes receiving liraglutide, semaglutide or tirzepatide over twelve months.
Europe PMC
An unreviewed preprint proposes a brain–brown-fat pathway contributing to tirzepatide-related weight loss in mice.
Europe PMC
A new analysis looks at how weight regain occurs after discontinuing semaglutide or tirzepatide, but more evidence is needed to understand the full implications.
Europe PMC
A case report describes improvement in prurigo nodularis after a man began semaglutide for obesity, without a change to his background skin treatment.
Europe PMC
This review discusses tirzepatide and SGLT2 inhibitors in heart failure with preserved ejection fraction and obesity. Evidence from separate treatments or trials does not establish that a combined regimen was tested or is suitable for an individual patient.
Europe PMC
A case report describes unilateral Graves’ disease developing in a woman receiving tirzepatide.
Europe PMC
A systematic review and meta-analysis explores the effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults without diabetes
Europe PMC
This small extension examined glycaemic changes after semaglutide withdrawal in adults with type 1 diabetes using automated insulin delivery. Its findings are specific to that specialist setting and do not support an independent change to insulin or another medicine.
Europe PMC
An observational study in npj Metabolic Health and Disease found associations between higher attained semaglutide doses and fewer subsequent diagnoses in several neuropsychiatric categories.
Europe PMC
Researchers in the Journal of Controlled Release investigated an experimental nanomicelle delivery system using laboratory models and mice with diet-induced obesity.
Europe PMC
This review examines semaglutide bioavailability and formulation development. Formulations, routes and food effects are not interchangeable. Technical delivery improvements do not, by themselves, establish a new clinical benefit or treatment recommendation.
Europe PMC
Research published in a recent study suggests that late-life semaglutide treatment may slow ageing and extend lifespan in female mice.
PubMed / NLM
A comprehensive review of methods for determining semaglutide in pharmaceutical formulations and biological matrices has been published.
Europe PMC
This prospective study followed 25 Japanese people with type 2 diabetes taking oral semaglutide over three months. It assessed dietary intake and body-composition measures. Its small size, population and formulation limit generalisation; it does not prove muscle preservation for people using other semaglutide products.
Europe PMC
Researchers investigate the direct effects of Semaglutide on male and female rat reproductive systems, beyond weight loss
PubMed / NLM
The linked publication reports a single case of skin improvement associated with tirzepatide-related weight loss. No abstract was available in the checked record. One case cannot establish causation, treatment efficacy or a new routine indication.
Europe PMC
This case report describes one adult with Prader–Willi syndrome and diabetes. A single reported response cannot establish effectiveness for the wider syndrome or define routine treatment guidance.
Europe PMC
This preprint compares blood-cell and bone-marrow changes in mice losing weight through tirzepatide or matched calorie restriction.
Europe PMC
The cited item in Expert Review of Clinical Pharmacology is an editorial, not a new clinical trial.
Europe PMC
The cited source is a narrative-review preprint, not a peer-reviewed clinical guideline or a new patient trial.
Europe PMC
A meta-analysis in the Journal of the American Heart Association did not find a clear association with atrial fibrillation or atrial arrhythmia; the uncertainty intervals included no difference.
PubMed / NLM
An American Journal of Surgery paper used a Markov model to project survival under different weight-management strategies for people with stage 5 chronic kidney disease.
ClinicalTrials.gov
Registry status checked on 3 October 2026: completed.
ClinicalTrials.gov
Registry status checked on 3 October 2026: completed.
ClinicalTrials.gov
Registry status checked on 3 October 2026: completed.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: active not recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: active not recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: active not recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: completed.
ClinicalTrials.gov
Registry status checked on 3 October 2026: not yet recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: not yet recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: not yet recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: active not recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: active not recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: active not recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: completed.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: active not recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: active not recruiting.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
ClinicalTrials.gov
Chugai announced on 28 September 2026 that obesity development of emugrobart would stop.
PubMed / NLM
A Childhood Obesity study analysed US commercial insurance claims from 2017–2019 for children aged 2–17 with obesity.
PubMed / NLM
This mechanistic review explores the gut–joint axis in metabolic osteoarthritis. It discusses potential targets and preliminary rationale. These hypotheses are not proof that a particular intervention improves clinical arthritis outcomes.
ClinicalTrials.gov
Registry status checked on 3 October 2026: recruiting.
Europe PMC
A study in Diabetes used leptin-deficient ob/ob mice to examine sex differences during three weeks of semaglutide treatment.
Europe PMC
A systematic review in Obesity examined seven randomised trials in acquired hypothalamic obesity.
Europe PMC
The linked record is a comment on a PCOS paper, and no abstract was available in the checked primary record. It does not provide enough detail here to substantiate weight-loss or fertility benefit claims. The underlying study must be identified and checked before those claims are reported.
Europe PMC
A twelve-week quasi-experimental study compared a virtual programme with physical-activity coaching against usual care.
MHRA
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update regarding the potential risk of pulmonary aspiration during general anaesthesia or deep sedation with GLP-1 and dual GIP/GLP-1 receptor agonists
MHRA
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has reminded healthcare professionals of the potential side effects and misuse of GLP-1 receptor agonists.
MHRA
The MHRA has issued a drug safety update regarding the risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) associated with Semaglutide (Wegovy, Ozempic and Rybelsus)
MHRA
The MHRA has issued a drug safety update regarding the transition to a new formulation of Rybelsus (semaglutide tablets), highlighting the risk of medication errors.
MHRA
The MHRA has issued a warning about falsified Mounjaro KwikPen 15mg pre-filled pens, which may pose a risk to users
MHRA
The MHRA has issued strengthened warnings on acute pancreatitis, including necrotising and fatal cases, for GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists.
MHRA
The MHRA has approved a once-daily Wegovy tablet for weight management in eligible adults in the UK.
Try a shorter search or clear a filter to see more.
Show all stories0 more to explore